Fairmount Funds Management LLC bought CBIO
December 4, 2025 · Form 4 insider transaction
Fairmount Funds Management LLC bought 1,360,000 shares of Crescent Biopharma, Inc. at $13.41 per share, a transaction worth $18.24M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
1,360,000
Price
$13.41
Total value
$18.24M
Role—
SecurityOrdinary Shares
Transaction codeP: Open-market purchase
Transaction dateDecember 4, 2025
Filing dateDecember 8, 2025
Shares owned after2,747,866
OwnershipIndirect
10b5-1 planNo
AmendedNo
Footnotes
Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.